Trial reportBMC oral health2026
Synergistic efficacy of a biomimetic hydroxyapatite-citrate complex for dentin hypersensitivity: an in vitro and clinical study.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the synergistic effect of a novel Hydroxyapatite (HAP)-Citrate complex toothpaste on dentinal tubule occlusion and the relief of dentine hypersensitivity (DH).
methodsFor the in vitro study, thirty bovine dentin discs were randomly divided into three groups with ten specimens each: group A, a test toothpaste (HAP, potassium citrate and NaF), group B, a control toothpaste (HAP and NaF), and group C, a placebo toothpaste (NaF only). After 3 and 7 days of simulated brushing, tubule occlusion and mineralized layer formation was assessed using Scanning electron microscopy (SEM). A 12-week, double-blind, randomized trial involving 129 subjects compared the test toothpaste to a bioactive glass-based positive control toothpaste and a placebo. The severity of DH, indicated by Schiff (air) and Yeaple (tactile), was evaluated at baseline, 2, 6, 8, and 12 weeks, with the last 4 weeks being a washout period. Data were analyzed using ANOVA to compare differences between groups, with a significance level set at p < 0.05.
resultsIn the in-vitro study, the HAP-Citrate complex toothpaste demonstrated rapid and effective occlusion. After 3 and 7 days, it achieved a dentinal tubule occlusion rate of 96.0 ± 2.1% and 99.7 ± 0.7%, significantly surpassing the placebo group (43.5 ± 10.1% and 76.4 ± 7.3%, respectively; p < 0.05). Notably, the HAP-Citrate complex exhibited superior deep-sealing capabilities compared to the standard HAP control toothpaste. At day 7, the HAP-Citrate group showed an intratubular occlusion depth of more than 40 μm (vs. 13 μm in the HAP control) and formed a surface mineralized layer of more than 5 μm thick (vs. 1 μm in the HAP control). In the clinical trial, the HAP-citrate toothpaste showed significant DH relief, with Schiff and Yeaple score improvements of 21.39% and 100.85% respectively at 8 weeks compared to placebo (p < 0.05), comparable to the positive control. Notably, the reduction in air-stimulus sensitivity was sustained at the 12-week follow-up, four weeks after the subjects discontinued the product use.
conclusionsThe novel HAP-citrate complex toothpaste can build deep, protective mineral seal on dentin tubules. Its clinically proven performance makes it a superior, science-backed choice for effective sensitivity management. REGISTRY: Chinese Clinical Trial Registry, TRN: ChiCTR2500115399, Registration date: 25 December 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.